Synthetic strategy and structure–activity relationship (SAR) studies of 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1, Lificiguat): a review-Reference-Cited by-同舟云学术

Synthetic strategy and structure–activity relationship (SAR) studies of 3-(5′-hydroxymethyl-2′-furyl)-1-benzyl indazole (YC-1, Lificiguat): a review

Published:2022 Issue:1 Volume:12 Page:251-264
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Yu Ko-Hua¹,Hung Hsin-Yi¹^ORCID

Affiliation:

1. School of Pharmacy College of Medicine, National Cheng Kung University, Tainan 701, Taiwan

Abstract

Since 1994, YC-1 (Lificiguat) has been synthesized, and many targets for special bioactivities have been explored, such as stimulation of platelet-soluble guanylate cyclase, indirect elevation of platelet cGMP levels, and inhibition of HIF-1 and NF-κB.

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/RA/D1RA08120A

Reference79 articles.

1. YC-1, a novel activator of platelet guanylate cyclase

2. Synthesis of 1-Benzyl-3-(5‘-hydroxymethyl-2‘-furyl)indazole Analogues as Novel Antiplatelet Agents

3. YC-1: A Potential Anticancer Drug Targeting Hypoxia-Inducible Factor 1

4. HIF-1 - and hypoxia-dependent immune responses in human CD4+CD25high T cells and T helper 17 cells

5. Maslinic Acid Induces Mitochondrial Apoptosis and Suppresses HIF-1α Expression in A549 Lung Cancer Cells under Normoxic and Hypoxic Conditions

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The modulated luminescent materials based on benzimidazole and indazole skeletons: Synthesis, crystal structure and Hirshfeld surface analysis;Journal of Molecular Structure;2024-09

2. HIF-1α is a “brake” in JNK-mediated activation of amyloid protein precursor and hyperphosphorylation of tau induced by T-2 toxin in BV2 cells;Mycotoxin Research;2024-02-06

3. Regulation of EZH2 protein stability: new mechanisms, roles in tumorigenesis, and roads to the clinic;eBioMedicine;2024-02

4. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens;Frontiers in Oncology;2023-07-10

5. Soluble Guanylyl Cyclase Activators—Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension;Molecules;2023-01-15